loading page

A new rapid titration protocol for lamotrigine that reduces the risk of skin rash
  • +11
  • Yoonhyuk Jang,
  • Jangsup Moon,
  • Narae Kim,
  • Tae-Joon Kim,
  • Jin-Sun Jun,
  • Yong-Won Shin,
  • Hyeyeon Chang,
  • Hye Ryun Kang,
  • Soon-Tae Lee,
  • Keun-Hwa Jung,
  • Kyung-Il Park,
  • Ki-Young Jung,
  • Kon Chu,
  • Sang Kun Lee
Yoonhyuk Jang
Seoul National University Hospital

Corresponding Author:[email protected]

Author Profile
Jangsup Moon
Seoul National University Hospital
Author Profile
Narae Kim
Seoul National University Hospital
Author Profile
Tae-Joon Kim
Ajou University School of Medicine and Graduate School of Medicine
Author Profile
Jin-Sun Jun
Kangnam Sacred Heart Hospital
Author Profile
Yong-Won Shin
Seoul National University Hospital
Author Profile
Hyeyeon Chang
National Center for Mental Health
Author Profile
Hye Ryun Kang
Seoul National University Hospital
Author Profile
Soon-Tae Lee
Seoul National University Hospital
Author Profile
Keun-Hwa Jung
Seoul National University Hospital
Author Profile
Kyung-Il Park
Seoul National University Hospital
Author Profile
Ki-Young Jung
Seoul National University Hospital
Author Profile
Kon Chu
Seoul National University Hospital
Author Profile
Sang Kun Lee
Seoul National University Hospital
Author Profile

Abstract

Aims Lamotrigine is one of the most widely used antiepileptic drugs, but it has a critical issue of a skin rash if the starting dose is too high or the escalation rate is too rapid. We investigated the efficacy and safety of a novel and rapid titration protocol for lamotrigine that takes only 11 days to reach a daily dose of 200 mg. Methods We prospectively enrolled 33 adult patients (age 18-85) who were diagnosed with epilepsy and started lamotrigine administration for the first time at a single tertiary hospital. Our new protocol starts with a subthreshold dose of the drug and then administer a stepwise-incremental dose until reaching the full therapeutic dose within 11 days. Results Of 29 patients analyzed, only two (6.9%) experienced idiosyncratic skin rash before the first follow-up visit at 2 weeks (±3 days). In addition, a therapeutic concentration was reached in more than 75% of studied patients after 2 weeks of lamotrigine administration Conclusion These findings demonstrate the value of the novel tolerance induction protocol for lamotrigine, which could widen the available application of lamotrigine in various situations.